JP7146771B2 - 操作されたＦｃコンストラクトに関する組成物及び方法 - Google Patents

操作されたＦｃコンストラクトに関する組成物及び方法 Download PDF

Info

Publication number
JP7146771B2
JP7146771B2 JP2019537119A JP2019537119A JP7146771B2 JP 7146771 B2 JP7146771 B2 JP 7146771B2 JP 2019537119 A JP2019537119 A JP 2019537119A JP 2019537119 A JP2019537119 A JP 2019537119A JP 7146771 B2 JP7146771 B2 JP 7146771B2
Authority
JP
Japan
Prior art keywords
domain
seq
amino acid
sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019537119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504143A5 (enExample
JP2020504143A (ja
Inventor
カルロス ジェイ． ボスケス
ジョナサン シー． ランシング
ダニエル オルティス
Original Assignee
モメンタ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モメンタ ファーマシューティカルズ インコーポレイテッド filed Critical モメンタ ファーマシューティカルズ インコーポレイテッド
Publication of JP2020504143A publication Critical patent/JP2020504143A/ja
Publication of JP2020504143A5 publication Critical patent/JP2020504143A5/ja
Priority to JP2022150723A priority Critical patent/JP7611880B2/ja
Application granted granted Critical
Publication of JP7146771B2 publication Critical patent/JP7146771B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
JP2019537119A 2017-01-06 2018-01-05 操作されたＦｃコンストラクトに関する組成物及び方法 Active JP7146771B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022150723A JP7611880B2 (ja) 2017-01-06 2022-09-21 操作されたＦｃコンストラクトに関する組成物及び方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762443495P 2017-01-06 2017-01-06
US62/443,495 2017-01-06
US201762510228P 2017-05-23 2017-05-23
US62/510,228 2017-05-23
US201762589473P 2017-11-21 2017-11-21
US62/589,473 2017-11-21
PCT/US2018/012488 WO2018129255A1 (en) 2017-01-06 2018-01-05 Compositions and methods related to engineered fc constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022150723A Division JP7611880B2 (ja) 2017-01-06 2022-09-21 操作されたＦｃコンストラクトに関する組成物及び方法

Publications (3)

Publication Number Publication Date
JP2020504143A JP2020504143A (ja) 2020-02-06
JP2020504143A5 JP2020504143A5 (enExample) 2021-02-18
JP7146771B2 true JP7146771B2 (ja) 2022-10-04

Family

ID=62791103

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019537119A Active JP7146771B2 (ja) 2017-01-06 2018-01-05 操作されたＦｃコンストラクトに関する組成物及び方法
JP2022150723A Active JP7611880B2 (ja) 2017-01-06 2022-09-21 操作されたＦｃコンストラクトに関する組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022150723A Active JP7611880B2 (ja) 2017-01-06 2022-09-21 操作されたＦｃコンストラクトに関する組成物及び方法

Country Status (9)

Country Link
US (3) US11220531B2 (enExample)
EP (1) EP3565588A4 (enExample)
JP (2) JP7146771B2 (enExample)
KR (1) KR102624254B1 (enExample)
CN (2) CN117886928A (enExample)
AU (1) AU2018205808B2 (enExample)
BR (1) BR112019013955A2 (enExample)
SG (2) SG10202107391YA (enExample)
WO (1) WO2018129255A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015252866B2 (en) 2014-05-02 2021-01-28 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered Fc constructs
EP3423572B1 (en) 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
US11623964B2 (en) * 2016-05-23 2023-04-11 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered Fc constructs
US11220531B2 (en) 2017-01-06 2022-01-11 Janssen Biotech, Inc. Engineered Fc constructs
BR112022003713A2 (pt) 2019-09-13 2022-08-09 CSL Behring Lengnau AG Multímeros de fc de igg recombinantes para o tratamento de doenças renais mediadas por imunocomplexo
CA3159705A1 (en) 2019-12-06 2021-06-10 CSL Behring Lengnau AG Stable compositions of fc multimers
GB202005879D0 (en) * 2020-04-22 2020-06-03 Petmedix Ltd Heterodimeric proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011517456A (ja) 2008-04-02 2011-06-09 マクロジェニクス，インコーポレーテッド ＨＥＲ２／ｎｅｕ特異的抗体およびその使用方法
WO2015168643A2 (en) 2014-05-02 2015-11-05 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556219B1 (fr) 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
US5426641A (en) 1994-01-28 1995-06-20 Bell Communications Research, Inc. Adaptive class AB amplifier for TDMA wireless communications systems
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1997047732A2 (en) 1996-06-14 1997-12-18 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US20090074839A1 (en) 1997-01-22 2009-03-19 Marton Milankovits Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
BRPI0620639A2 (pt) 2006-12-21 2011-11-22 Micromet Ag anticorpos de cadeia simples biespecìficos e composição farmacêutica compreendendo os mesmos
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
KR20100021601A (ko) 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
KR101580937B1 (ko) 2007-06-01 2015-12-31 유니버시티 오브 매릴랜드, 발티모어 면역글로불린 불변영역 Ｆｃ 수용체 결합제
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
WO2010042481A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
WO2010065578A2 (en) 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
US10865233B2 (en) * 2008-12-18 2020-12-15 Dana-Farber Cancer Institute, Inc. NKG2D-fc for immunotherapy
BRPI1006998A2 (pt) 2009-01-23 2015-08-25 Biogen Idec Inc Polipeptídeos fc estabilizados com função efetora reduzida e métodos de uso
US8858948B2 (en) 2009-05-20 2014-10-14 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
EP2432451A2 (en) 2009-05-20 2012-03-28 Children's Medical Center Corporation Compositions for the treatment of metastatic cancer and methods of use thereof
CN102549016B (zh) 2009-06-30 2015-05-06 研究发展基金会 免疫球蛋白fc多肽
NZ598962A (en) 2009-09-16 2014-12-24 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
PT2486141T (pt) 2009-10-07 2018-05-09 Macrogenics Inc Polipéptidos contendo uma região fc que apresenta uma função efectora melhorada, devido a modificações do grau de fucosilação, e métodos para a sua utilização
CA2781539C (en) 2009-11-23 2021-07-20 Amgen Inc. Monomeric antibody fc
GB0922209D0 (en) 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
CA2800173C (en) 2010-05-21 2019-05-14 Ulrik Nielsen Bi-specific fusion proteins
DK2591099T3 (da) 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
AU2011282579B2 (en) 2010-07-28 2014-10-23 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
IN2013MN01438A (enExample) 2011-03-17 2015-06-12 Univ Ramot
NZ608724A (en) 2011-03-25 2015-12-24 Glenmark Pharmaceuticals Sa Hetero-dimeric immunoglobulins
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
CA2877363A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
MX2015002269A (es) 2012-08-20 2015-07-06 Gliknik Inc Moleculas con actividad de union al antigeno y al receptor fc gamma polivalente.
BR112015008663B1 (pt) 2012-10-17 2021-01-12 CSL Behring Lengnau AG Uso de uma quantidade eficaz de uma proteína polimérica compreendendo seis unidades demonômero de polipeptídeo
CN104558194B (zh) 2013-10-17 2018-04-27 泰州迈博太科药业有限公司 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途
JP2016538283A (ja) * 2013-11-13 2016-12-08 ザイムワークス，インコーポレイテッド Ｅｇｆｒ及び／またはｈｅｒ２を標的にする一価抗原結合性構築物及びその使用
WO2015095684A1 (en) 2013-12-20 2015-06-25 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
BR112016016411A2 (pt) * 2014-01-15 2017-10-03 Hoffmann La Roche VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS
EP3094647A1 (en) * 2014-01-15 2016-11-23 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn- and maintained protein a-binding properties
AU2015226101B2 (en) 2014-03-05 2019-08-22 Ucb Biopharma Sprl Multimeric Fc proteins
TW201619188A (zh) 2014-03-05 2016-06-01 優稀美生物醫藥公司 多聚體Ｆｃ蛋白質
JP2017513481A (ja) 2014-04-16 2017-06-01 ユーシービー バイオファルマ エスピーアールエル 多量体Ｆｃタンパク質
NZ726514A (en) 2014-05-29 2019-01-25 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
EP3423572B1 (en) 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
US11623964B2 (en) 2016-05-23 2023-04-11 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered Fc constructs
US11220531B2 (en) 2017-01-06 2022-01-11 Janssen Biotech, Inc. Engineered Fc constructs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011517456A (ja) 2008-04-02 2011-06-09 マクロジェニクス，インコーポレーテッド ＨＥＲ２／ｎｅｕ特異的抗体およびその使用方法
WO2015168643A2 (en) 2014-05-02 2015-11-05 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Robert L. Shields et al.，The Journal of Biological Chemistry，2001年，Vol. 276, No. 9，6591-6604

Also Published As

Publication number Publication date
CN117886928A (zh) 2024-04-16
US20240209040A1 (en) 2024-06-27
US11220531B2 (en) 2022-01-11
SG11201906139VA (en) 2019-08-27
RU2019124710A3 (enExample) 2021-05-26
BR112019013955A2 (pt) 2020-02-11
US20190345206A1 (en) 2019-11-14
AU2018205808B2 (en) 2025-02-06
WO2018129255A1 (en) 2018-07-12
AU2018205808A1 (en) 2019-07-25
EP3565588A4 (en) 2020-12-16
CN110650748A (zh) 2020-01-03
KR102624254B1 (ko) 2024-01-12
SG10202107391YA (en) 2021-08-30
RU2019124710A (ru) 2021-02-08
US11827682B2 (en) 2023-11-28
JP2022191261A (ja) 2022-12-27
JP7611880B2 (ja) 2025-01-10
CA3049383A1 (en) 2018-07-12
JP2020504143A (ja) 2020-02-06
US20220267388A1 (en) 2022-08-25
CN110650748B (zh) 2024-01-02
KR20190099333A (ko) 2019-08-26
EP3565588A1 (en) 2019-11-13

Similar Documents

Publication Publication Date Title
JP7295301B2 (ja) 操作されたＦｃコンストラクトに関する組成物及び方法
JP7146771B2 (ja) 操作されたＦｃコンストラクトに関する組成物及び方法
US20220267460A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
RU2816477C2 (ru) КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ Fc-КОНСТРУКЦИЯМИ
CA3049383C (en) Compositions and methods related to engineered fc constructs
CN113164592A (zh) 与工程化Fc-抗原结合结构域构建体有关的组合物和方法
HK40005981B (en) Compositions and methods related to engineered fc constructs
HK40005981A (en) Compositions and methods related to engineered fc constructs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190910

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210105

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210322

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210526

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210528

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220516

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220823

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220921

R150 Certificate of patent or registration of utility model

Ref document number: 7146771

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250